Active Ingredient History

  • Now
Balsalazide, a prodrug that is enzymatically cleaved by bacterial azoreduction to release equimolar quantities of mesalamine (5-aminosalicylic acid or 5-ASA) in the colon, an anti-inflammatory drug. The mechanism of action of 5-ASA is unknown, but appears to be local to the colonic mucosa rather than systemic. Balsalazide is indicated for the treatment of mildly to moderately active ulcerative colitis. Most frequently reported adverse events are: headache, abdominal pain, diarrhea, nausea, vomiting, respiratory infection, and arthralgia. The use of orally administered antibiotics could, theoretically, interfere with the release of mesalamine in the colon.   NCATS

  • SMILES: OC(=O)CCNC(=O)c1ccc(cc1)\N=N\c2ccc(O)c(c2)C(=O)O
  • Mol. Mass: 357.32
  • ALogP: 2.71
  • ChEMBL Molecules:
More Chemistry

Drug Pricing (per unit)

United States

$0.2197 - $2.5704
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

3-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazinylidene)-6-oxocyclohexa-1,4-diene-1-carboxylic acid | 5-[4-(2-carboxy-ethylcarbamoyl)-phenylazo]-2-hydroxy-benzoic acid | 5-(carboxyethylcarbamoyl-4-phenylazo)salicylic acid | balsalazid | balsalazida | balsalazide | balsalazide disodium | balsalazide sodium | balsalazido | balsalazidum | balsalazine | benzoic acid, 5-((4-(((2-carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxy-, disodium salt | bx661a | bx 661a | bx-661a | colazal | colazide | (e)-5-((4-(((2-carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid | (e)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid | giazo


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue